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Abstract
Background: Antimicrobial resistance (AMR) is a recognized threat to global public health. Increasing AMR and a
dry pipeline of novel antimicrobial drugs have put AMR in the international spotlight. One strategy to combat AMR
is to reduce antimicrobial drug consumption. Governments around the world have been experimenting with different
policy interventions, such as regulating where antimicrobials can be sold, restricting the use of last-resort antimicrobials,
funding AMR stewardship programs, and launching public awareness campaigns. To inform future action, governments
should have access to synthesized data on the effectiveness of large-scale AMR interventions. This planned systematic
review will (1) identify and describe previously evaluated government policy interventions to reduce human
antimicrobial use and (2) estimate the effectiveness of these different strategies.
Methods: An electronic search strategy has been developed in consultation with two research librarians. Seven
databases (MEDLINE, CINAHL, EMBASE, CENTRAL, PAIS Index, Web of Science, and PubMed excluding MEDLINE) will be
searched, and additional studies will be identified using several gray literature search strategies. To be included, a study
must (1) clearly describe the government policy and (2) use a rigorous design to quantitatively measure the impact of
the policy on human antibiotic use. The intervention of interest is any policy intervention enacted by a government or
government agency in any country to change human antimicrobial use. Two independent reviewers will screen for
eligibility using criteria defined a priori.
Data will be extracted with Covidence software using a customized extraction form. If sufficient data exists, a
meta-analysis by intervention type will be conducted as part of the effectiveness review. However, if there are
too few studies or if the interventions are too heterogeneous, data will be tabulated and a narrative synthesis
strategy will be used.
Discussion: This evidence synthesis is intended for use by policymakers, public health practitioners, and researchers to
inform future government policies aiming to address antimicrobial resistance. This review will also identify gaps in the
evidence about the effectiveness of different policy interventions to inform future research priorities.
Systematic review registration: PROSPERO CRD42017067514.
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Background
Antimicrobial resistance (AMR) is widely recognized as a
serious threat to global public health. One estimate suggests
that resistance is currently responsible for 700,000 deaths
per year, a death toll that is projected to reach 10 million a
year by 2050 [1]. The potential for AMR has been recog-
nized since the earliest days of antibiotics [2]; yet, the
misuse and overuse of antimicrobials have persisted over
decades, contributing to the development of resistance.
Overuse of antibiotics exerts a selection pressure on mi-
crobes and accelerates the evolution of resistant strains of
disease-causing organisms [3]. In the past, the threat of
AMR was addressed by developing novel antimicrobial
agents; however, there have not been any such novel agents
developed in over 20 years, and few new potential agents
are in development [4–6]. As a result, there is increasing
awareness around the need to minimize the development
of AMR through better conserving the effectiveness of
existing antimicrobials.
AMR is a complex and multi-faceted problem, and
intervening to minimize resistance is difficult. A key part
of the global strategy on AMR is promoting the appropri-
ate use of antimicrobials; inappropriate use and overuse of
antimicrobials are major drivers of resistance [3]. Evidence
suggests that reducing antibiotic use is associated with
lower rates of resistance [3]. Two systematic reviews have
linked community antimicrobial use to resistance; one
found that individuals prescribed an antibiotic in primary
care developed resistance to that antibiotic with detectable
effects for up to a year [7], while the other found higher
resistance rates among pathogens circulating in areas with
higher antibiotic use [8]. Mathematical modeling suggests
that reductions in antibiotic use would result in lower
resistance rates because genetically less “fit” resistant
strains would be outcompeted by susceptible strains [9].
Recent analyses of a Scottish intervention found substantial
decreases in methicillin-resistant Staphylococcus aureus
(MRSA) and Clostridium difficile infections associated with
decreases in prescribing of key antibiotics [10, 11]. Redu-
cing antimicrobial use among humans is important given
the relationship between hospital and community infec-
tions; the same Scottish study found that prevalence of
MRSA in the community was predicted by hospital MRSA
rates. Stewardship activities within the community were
associated with a 32% reduction in community MRSA,
while hospital-based interventions were responsible for an
additional 37% reduction in community MRSA [11].
Reducing antimicrobial use is, therefore, one of the most
common strategies that has been pursued to reduce AMR,
and antimicrobial use is one of the most commonly mea-
sured intervention evaluation indicators. Many hospitals, for
example, have implemented AMR stewardship programs to
reduce physician prescribing [12]. Governments—which
have various policy levers at their disposal—have also had
success at reducing antimicrobial use. Mexico [13], Brazil
[14], and Chile [15], for example, all saw reductions in
antibiotic use after implementing policies to prevent over-
the-counter sales of antibiotics. Less direct interventions
have also reduced antibiotic use; in Canada, a policy to
provide free universal influenza immunization was associ-
ated with a 64% reduction in inappropriate antibiotic pre-
scriptions for influenza [16].
Using government policy to promote public health is
generally well-worth considering when challenges require
widespread and uniform compliance with a defined set of
minimum standards [17]; in that vein, research to date
suggests that government-level intervention may play a
key role in reducing AMR [18]. Currently, however, global
antimicrobial use is increasing; between 2000 and 2010,
there was a 36% global increase in antibiotic use, 75% of
which came from five of the world’s fastest growing econ-
omies: Brazil, Russia, India, China, and South Africa [19].
While the importance of government-level interven-
tion is clear, to our knowledge, there has not yet been a
systematic review evaluating the extent to which differ-
ent government policy interventions successfully reduce
antimicrobial use. This gap is worth filling urgently con-
sidering that many governments around the world are
actively considering numerous types of policy interven-
tions that could reduce antimicrobial use, utilizing policy
levers such as legislation, taxation, economic incentives,
funding support, public awareness campaigns, and regu-
lation of professionals and businesses whose work might
affect AMR [17]. The magnitude of AMR’s combined
threat to human health and economic development [1]
is already incentivizing governments to take a greater
role in addressing AMR. Given the World Health Orga-
nization’s recent call for the development of National
Action Plans on AMR [20], a focus on the potential im-
pact of government policy interventions on antimicro-
bial use is extremely timely. In light of these motivations
and challenges, this systematic review intends to support
evidence-informed action on AMR at the government
level, by identifying, describing, and assessing the impact
of government policy interventions on human anti-
microbial use. More specifically, this systematic review
aims to produce the following: (1) a descriptive review
that identifies and describes the government policy in-
terventions that have been implemented and evaluated
with the objective of changing antimicrobial use in
humans and (2) an effectiveness review that assesses the
impact of these government policy interventions on re-
ducing human antimicrobial use.
Methods
Protocol and registration
This systematic review protocol has been reported in ac-
cordance with the Preferred Reporting Items for Systematic
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Review and Meta-Analysis Protocols (PRISMA-P) guide-
lines [21] (see details in Additional file 1). Our review will
be carried out in accordance with this protocol, and details
of any changes to this protocol will be reported in the final
review manuscript. This study has been registered in
PROSPERO, the International Prospective Register of Sys-
tematic Reviews (Registration number CRD42017067514).
Criteria for including studies in this review
Types of study designs
For the descriptive review, we will include any study that
quantitatively describes the impact of a government policy
intervention to reduce inappropriate antimicrobial use. In-
clusion of all quantitative study designs allows us to identify
a broad range of policy interventions and facilitates our goal
of identifying and describing the government policy inter-
ventions to address antimicrobial consumption that have
been implemented and evaluated to date (Table 1).
For the effectiveness review, our goal is to assess the
impact of government policy interventions on the quan-
tity of antimicrobials consumed by humans. We will in-
clude experimental designs like randomized controlled
trials (including stepped wedge designs) and quasi-
experimental designs like interrupted time-series ana-
lyses and controlled before-and-after studies. Quasi-
experimental designs will need to meet the minimum
methodological requirements of the Cochrane Collabo-
ration’s Effective Practice and Organization of Care
(EPOC) group. This means that all controlled studies,
including controlled before-and-after studies, random-
ized controlled trials, and non-randomized controlled
trials, must have at least two intervention and two con-
trol sites and interrupted time-series studies must have
at least three measurements pre- and post-intervention
to be included. Uncontrolled before/after studies with at
least three measurements pre- and post-intervention
may also be included if it is possible to re-analyze the
data using an interrupted time-series analysis. We antici-
pate most included studies will evaluate impact using
routinely collected data from before and after the inter-
vention’s implementation; a recent review of government
policy interventions addressing dietary sodium con-
sumption found this to be the most popular study design
[22]. Qualitative studies, editorials, commentaries,
Table 1 Summary of inclusion/exclusion criteria for phase 1 and phase 2 of screening
Criteria Include if Exclude if
Phase 1/
title and
abstract
screening
1) The study assesses a primary
outcome measure of interest.
Study reports on human antimicrobial use,
including consumption, prescribing, dosing,
and sales of an antibiotic, antiviral, antiparasitic,
or antifungal drug.
Study does not report on antimicrobial
use or only reports on antimicrobial use
in animals or agriculture.
2) The study quantitatively evaluates
the effect of an intervention.
Study is a quantitative impact evaluation. Study is a qualitative study, editorial,
commentary, review, or synthesis or
does not evaluate the impact of an
intervention.
3) A policy intervention is evaluated. A policy intervention using education,
persuasion, incentivization, coercion,
training, restriction, changing the physical
or social context, modeling appropriate
behavior, or reducing barriers to action
is being evaluated.
Intervention was not a change to a policy (e.g.,
clinical study).
Phase 2/
full-text
screening
1) The study assesses a primary
outcome measure of interest.
Study reports on human antimicrobial use,
including consumption, prescribing, dosing,
and sales of an antibiotic, antiviral, antiparasitic,
or antifungal drug.
Study does not report on antimicrobial
use or only reports on antimicrobial use
in animals or agriculture.
2) The study quantitatively evaluates
the effect of an intervention.
Study is a quantitative impact evaluation. Study is a qualitative study, editorial, commentary,
review, or synthesis or does not evaluate the
impact of an intervention.
3) The study reports on a policy
intervention enacted at the
government level.
The policy intervention was enacted by a
government or government agency at the
federal, state, provincial, or municipal level.
Intervention was not enacted by a
government (e.g., intervention was
enacted in a single hospital or
network of hospitals).
4) The intervention is clearly
described
The study provides a description that
includes the intervention’s aim, enacting
government authority, timing, and form.
The study does not describe the aim,
governing body, timing of the
intervention, or form of the intervention.
Effectiveness review only:
5) The study design is sufficiently
rigorous to meet the minimum
methodological requirements of
the Cochrane Collaboration’s
EPOC group
Effectiveness review only: Study design is
experimental or quasi-experimental, such
as randomized controlled trial, interrupted
time series, and controlled before/after
study, or it can be re-analyzed to meet
this standard.
Effectiveness review only: Study does
not have a control group or use
pre-intervention data and cannot be
re-analyzed.
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reviews, and other syntheses will be excluded; however,
the reference lists of relevant reviews and syntheses will
be hand-searched to identify other potentially relevant
studies.
Types of participants
The impact of a government policy may be evaluated at
any level, from the population level to the single hospital
or clinic level; for example, a study investigating the impact
of a national guideline might evaluate the impact on anti-
biotic sales at a national level, but it could also evaluate the
impact on prescribing rates in a single hospital. However,
in their statistical analysis, studies may include data from
anyone involved in the sale, purchase, prescription, or con-
sumption of antimicrobial drugs such as patients, health
professionals, hospitals, pharmacies, and other healthcare
facilities. Studies that evaluate interventions in any country
or simultaneously in multiple countries (e.g., European
Union) are eligible for inclusion.
Types of interventions
Any policy intervention enacted by a government to
reduce human antimicrobial use will be included. Inter-
ventions may be population-based, or targeted to specific
groups such as health professionals. To be included, a
study must clearly describe the government policy by
providing a description that includes the intervention’s
aim, enacting government authority, timing, and form.
Globally, many levels of government have jurisdiction
over health issues. As such, we will follow an inclusive
approach to defining “government.” A study is eligible for
inclusion if the evaluated policy intervention is enacted by
any level of government, including national, state, provin-
cial, regional, and municipal governments, or by a
government-controlled agency, ministry, or department.
Studies evaluating interventions developed by individual
hospitals, pharmacies, and other healthcare facilities will not
be included, even if these healthcare facilities are owned,
operated, governed, or otherwise controlled by govern-
ments. As such, a study evaluating the impact of an audit
and feedback program developed by a single hospital or
even a network of healthcare facilities would not be eligible.
Policy interventions will be defined in accordance with
the Behavior Change Wheel framework; as such, policy
interventions are defined as those that create change in
antimicrobial use through education, persuasion, incen-
tivization, coercion, training, restriction, changing the
physical or social context, modeling appropriate behav-
ior, or reducing barriers to action [23]. Examples of such
policy interventions at the government level would in-
clude the following: regulating where antimicrobials can
be sold, restricting the use of last-resort antibiotics, or
launching public awareness campaigns. Comparators or
control groups may include the absence of the government
policy or comparison with another policy. Eligible interven-
tions can target all antimicrobials (e.g., all antibiotics), spe-
cific antimicrobials, or particular groups of antimicrobials
(e.g., 4C antibiotics).
Types of outcomes
Many countries do not collect sufficient regional or na-
tional surveillance data on AMR to allow analysis of the
impact of policy-level interventions on resistance, and sur-
veillance definitions of resistance vary between countries
[24]. As such, we chose to focus on antimicrobial use,
which is an intermediary between policy interventions and
AMR. Better data exists for this outcome, as prescribing
and sales of antibiotics are often captured as routine health
administrative data. Relevant outcome measures of anti-
microbial use include self-reported antimicrobial consump-
tion, measured antimicrobial consumption, antimicrobial
prescribing, antimicrobial dosing, and/or antimicrobial
sales. Secondary outcomes will include any other reported
beneficial or adverse outcomes related to the intervention.
These secondary outcomes might include, for example,
changes in rates of AMR, or increases and decreases in the
rates of hospital re-admission or return clinic visits, result-
ing from a government policy intervention to reduce
human antimicrobial consumption.
Information sources
Seven electronic databases will be searched: MEDLINE,
CINAHL, EMBASE, PAIS Index, Cochrane Central Regis-
ter of Controlled Trials (CENTRAL), and Web of Science
from inception to March 2017. PubMed will also be
searched for relevant articles that are not indexed in
MEDLINE, using the search filter developed by the Canad-
ian Agency for Drugs and Technologies in Health [25].
The MEDLINE search strategy is available in Table 2; the
search strategies for all databases are in Additional file 2.
The search strategies for the four biomedical databases
(MEDLINE, EMBASE, CENTRAL, and PubMed) include
search terms for 172 antibiotics names; this list of antibi-
otics was used in the recent Cochrane review of interven-
tions to improve antibiotic prescribing in hospitals [12].
The search strategies for the social science and allied health
databases (CINAHL, PAIS Index, Web of Science) in-
cluded the generic terms “antibiotic” and “antimicrobial”
instead of specific antibiotic names. No date or language
limits have been applied; we will endeavor to translate
studies that are not in languages spoken by members of
the study team (i.e., English and French). To identify gray
literature, we will use keywords to conduct targeted web
searching to identify government and civil society reports
and hand-search reference lists of included studies to iden-
tify non-indexed articles. We will also use the ProQuest
Dissertations and Theses database to identify dissertations
on this topic. After full-text screening, we will also contact
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six subject-matter experts—one from each WHO
region—to identify any additional studies from their region
that meet our inclusion criteria. This search strategy was
designed in consultation with a health science research li-
brarian and a government information research librarian at
the University of Ottawa. The search strategy has been
peer-reviewed using PRESS [26].
Screening and eligibility
We anticipate that some studies may not clearly state in the
title or abstract that the intervention is based on a govern-
ment policy intervention. To ensure that these articles are
not inadvertently excluded, we will conduct screening and
eligibility assessment in two stages. First, at the title/abstract
screening stage, articles will be assessed to determine if they
meet a set of basic criteria. Second, at the full-text review
stage, articles will be assessed thoroughly to determine
whether the study meets the remaining inclusion/exclusion
criteria. The inclusion/exclusion criteria for both stages are
listed in Table 1. Conference abstracts and proceedings will
be eligible for inclusion in the descriptive review if they
provide sufficient detail to describe the intervention. How-
ever, given that conference abstracts often differ in major
ways from the final published papers [27], they will be ex-
cluded from the analysis in the effectiveness review.
Data management and extraction
Search results from all electronic databases will be ag-
gregated using EndNote X7 software. De-duplication will
be carried out using the methods described by Bramer
et al. [28] which aims to reduce the number of false du-
plicates excluded while minimizing the need for manual
de-duplication. Title/abstract screening, full-text review,
data extraction, and risk of bias assessment will be car-
ried out independently by two reviewers. Any disagree-
ments between reviewers will be resolved by consensus
or in consultation with a third reviewer (SJH) if needed.
A PRISMA diagram will be generated to summarize the
flow of studies through the stages of the review [29].
Covidence software [30] will be used for screening. Data
extraction will be conducted using a customized data ex-
traction tool that will be pilot-tested in advance. Table 3
Table 3 Data extraction fields
General information Authors
Publication year
Journal
Country of study
Study characteristics Intervention aim
Study aim
Study design
Study duration, including duration of
pre-intervention period and duration
of follow-up
Study participants Description of population of interest
Method of recruitment
Inclusion/exclusion criteria for study
participants
Sample size calculation/power calculation
Intervention characteristics Enacting government authority
Description of policy intervention
Description of intervention groups
Number of intervention groups
Intervention duration and timing
Data analysis Type of analyses conducted
Statistical tests conducted
Confounders
Intervention effects Baseline and post-intervention results
Estimates of effect, including by time or
subgroup as appropriate
Secondary outcomes: beneficial outcomes
Secondary outcomes: adverse events
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summarizes the data that will be extracted from each in-
cluded study.
Quality assessment and risk of bias
Studies that meet the inclusion criteria for the effective-
ness review will be assessed for bias using the risk of bias
criteria developed by Cochrane’s EPOC group [31] which
is based upon Cochrane’s Risk of Bias Tool [32] and pro-
vides advice on assessing randomized trials, controlled
before-after studies, and interrupted time-series studies.
Studies will be assessed with regard to selection bias, per-
formance bias, detection bias, attrition bias, reporting bias,
and other sources of bias. For controlled studies, we will
examine baseline imbalances in antibiotic prescribing
levels and population age and sex/gender distributions.
Studies will be assessed as “low risk of bias,” “high risk of
bias,” or “unclear risk of bias” on each criterion, and a
summary table will be produced for each study.
Strategy for analysis
Descriptive review
Data collected for the descriptive review of government
policy interventions will be tabulated and summarized nar-
ratively. Articles will be categorized into seven groups by
policy type based on the Behavior Change Wheel frame-
work [23]: communication/marketing, guidelines, fiscal,
regulation, legislation, environmental/social planning, and
service provision. We will produce summary figures to re-
port on the characteristics of each intervention type.
Effectiveness review
The government policy interventions that we identify
are likely to be implemented across many populations,
settings, and healthcare systems and with different goals.
Some studies may aim to reduce all antimicrobial use,
while others may target inappropriate antimicrobial use,
or aim to reduce the use of specific antimicrobial agents.
Given this diversity, it would be useful to generate esti-
mates of effect by policy type. Therefore, if appropriate,
we will conduct meta-analyses as part of our effective-
ness review using the data from those studies that
employed a rigorous study design. To be included in the
meta-analysis, quasi-experimental studies will need to
meet the minimum methodological requirements of the
EPOC group. The two preferred analysis methods for
interrupted time-series studies are segmented regression
analysis with time trends before and after the interven-
tion adjusting for autocorrelation and any periodic
changes, or ARIMA analysis. Results for outcomes can
be presented as changes along two dimensions: change
in level, which is the immediate effect of the interven-
tion, and change in slope, which is the change in the
trend from pre- to post-intervention. Change in level is
measured as the difference between the fitted value for
the first post-intervention data point (e.g., 1 month after
the intervention) minus the predicted outcome for the
first post-intervention data point based on the pre-
intervention slope only. Change in slope is the change in
the trend from pre- to post-intervention and can be used
to determine the long-term effect of the intervention.
Since the interpretation of changes in slope can be diffi-
cult, we anticipate presenting the long-term effects of
the interventions as proposed for the immediate effects:
for example, the difference between the fitted value
6 months post-intervention (half a year after the inter-
vention) minus the predicted outcome 6 months post-
intervention based on the pre-intervention slope only.
As appropriate, effects after 1 year, 2 years, etc., will be
measured similarly. Where possible, we will re-analyze
the results of any interrupted time-series studies that
have not used these analytic strategies; we will also re-
analyze the results of uncontrolled before and after stud-
ies using segmented regression analysis if the studies
have at least three measurements pre- and post-
intervention. Where necessary, time series data will be
extracted from tables and figures using a software pack-
age that reads values from images.
If feasible and appropriate, meta-analysis will be con-
ducted for each category of policy described in the de-
scriptive review. We do not anticipate that studies will
share a common unit of measurement; as such, individual
study effect estimates will be generated for continuous
outcomes using standardized mean differences, and odds
ratios will be converted to standardized mean difference.
A random-effects model will be used for meta-analysis.
We will present forest plots to explore variation due to
the inclusion of non-randomized studies. If more than 10
studies are included in the meta-analysis, we will investi-
gate publication bias using funnel plots. Asymmetry will
be assessed visually and using the Egger test [32], and add-
itional exploratory analyses will be conducted if we iden-
tify evidence of reporting bias. If individual studies report
the necessary data, we will undertake a sex- and gender-
based analysis to determine whether government inter-
ventions have differential effects across these subgroups.
Additionally, if we determine that there are sufficient sex-
and gender-based data from studies on a specific policy
(e.g., restriction of over-the-counter antimicrobial sales),
we will determine whether meta-analysis is feasible in this
case. Sensitivity analyses will be conducted to consider the
impact of dropping weaker study designs and studies at
high risk of bias.
We expect to see substantial variability across studies
and will explore this using the I2 statistic [33]. In line
with the Cochrane Handbook’s guideline that an I2 stat-
istic > 50% may indicate substantial heterogeneity [32],
we will pool studies and conduct exploratory subgroup
analyses if we find an I2 greater than this value. Planned
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subgroup analyses include interventions that have been
implemented in low- and middle-income countries and
interventions that targeted particular audiences, for ex-
ample, health care providers.
Should meta-analysis not be feasible, a narrative review
and structured synthesis of the evidence will be conducted
using the studies with rigorous study designs. Within and
across the categories of policy intervention described above,
we will report on ranges of effects, heterogeneity, and qual-
ity of the evidence. If appropriate, we will also report on the
intervention effects by target population (e.g., health profes-
sionals vs. general public) and, if data are available, by sex
and gender.
Missing data
Where necessary statistical data are missing (e.g., stand-
ard deviations), we will contact the study authors dir-
ectly by using the email address of the corresponding
author provided in the article or by searching the Inter-
net for another email address for the corresponding au-
thor if the published address is invalid. Authors will be
contacted twice before data are marked as missing. Any
missing data that we are not able to obtain will be docu-
mented in the data extraction form.
If we identify cluster randomized trials that have not ap-
propriately accounted for the unit of randomization, we
will contact the authors for an estimate of the intra-
cluster correlation coefficient or use external databases to
impute an appropriate estimate to adjust for clustering.
Interpretation of review findings
The Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) system for rating the quality
of evidence will be used in presenting the findings of this
systematic review, as recommended by the Cochrane Col-
laboration [34]. The major outcomes for the effectiveness
review will be presented in a summary of findings table.
Discussion
To our knowledge, this will be the first systematic review to
investigate the range of government interventions on anti-
biotic use and to consider the impact of government policy
or regulatory action on antibiotic use. In identifying and de-
scribing government-level interventions (aim 1) using a sys-
tematic search strategy, we will be creating a valuable tool
for policymakers. Since we will be conducting this search
systematically, we will be maximizing our likelihood of
identifying the full set of government policy interventions
that have been implemented and evaluated to date. In
transparently synthesizing evidence that assesses the effect-
iveness of these interventions, we can offer higher-quality
evidence from around the world to inform the consider-
ation, prioritization, and adoption of new government pol-
icies to reduce human antimicrobial use. The identification
of any gaps in the evidence about the effectiveness of differ-
ent government policy interventions will also help inform
future priorities for researchers and research funders.
Strengths and limitations
As the first systematic review to focus on government
policy interventions addressing AMR, the review will
provide valuable information for policymakers, public
health practitioners, and researchers. Our search strategy
has been carefully designed in consultation with two re-
search librarians at the University of Ottawa—a health
research librarian and a government research librar-
ian—to incorporate databases from multiple academic
disciplines and to employ several gray literature search-
ing techniques to assist in locating relevant non-
academic information sources. The protocol has been
designed to meet the Cochrane Collaboration’s standards
for conducting a systematic review.
We recognize the potential for publication bias in this re-
view, particularly since much of the data we seek may not
reside in easily searchable databases of peer-reviewed aca-
demic literature. We have gone to great lengths in designing
this study to minimize the impact of such publication bias.
First, we consulted with an additional librarian focused on
government research to identify strategies for identifying gov-
ernment documents online. Second, we will be consulting
with subject-matter experts to identify other sources. These
two mechanisms, along with hand-searching reference lists
of articles, will assist us in identifying the relevant literature.
A second concern for this study is data quality. Since we
are investigating government policy interventions, we do
not expect to identify, for example, many randomized
controlled studies. Although there is a greater risk of bias
associated with quasi-experimental analyses, we have
chosen to include these studies in addition to randomized
controlled trials in both the descriptive and effectiveness
reviews. In so doing, we will identify a broader range of
government policy interventions, rather than identifying
only those that suit the randomized controlled design. For
the effectiveness review, we have chosen to include quasi-
experimental studies, but to analyze only those studies
with more rigorous study designs. This way we can place
greater confidence in the estimates of effectiveness in
these studies as they must, at the very least, include con-
trol groups or pre-intervention data. Additionally, all stud-
ies will be analyzed for risk of bias and in accordance with
GRADE quality of evidence criteria.
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